CLINICAL TRIAL: RAGE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项第二阶段研究是一项双盲、安慰剂对照、随机、多中心研究，评估使用PF-04494700治疗18个月的有效性和安全性。随机分为3组的参与者将分别接受20 mg、5 mg和安慰剂胶囊。这项研究将招募大约399名年龄在50岁或以上的参与者，他们被诊断为轻度至中度阿尔茨海默病，从MMSE评分14-26分可以看出。霍华德大学的网站将招募和监测399条参与研究的裤子中的15条。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This Phase 2 study is a double-blind, placebo-controlled, randomized, multicenter study evaluating the efficacy and safety of 18 months of treatment sith PF-04494700. Participants radomized to 3 treatment groups will receive 20mg, 5mg and placebo capsules respectively. The study will recruit approximately 399 participants that are 50 years or older and diagnosed with mild to moderate AD as will be indicated from MMSE scores of 14-26. The Howard University site will recruit and monitor 15 of the 399 particpants in the study.